<DOC>
	<DOCNO>NCT02946034</DOCNO>
	<brief_summary>Single arm , open-label experimental trial 12 week Viekira Pak treatment ± ribavirin adult chronic kidney disease hepatitis C .</brief_summary>
	<brief_title>Viekira Pak Treatment Patient With Chronic Kidney Disease Hepatitis C</brief_title>
	<detailed_description>The objective study evaluate effect paritaprevir/ritonavir , ombitasvir , dasabuvir ( refer Viekira Pak ) ± ribavirin adult advance CKD estimate glomerular filtration rate ( eGFR ) less 45ml/min infected hepatitis C virus ( HCV ) genotype 1 determine effect treatment traditional novel marker kidney function cardiovascular disease risk patient advance CKD . During course prospective , single arm treatment trial , measure currently accept marker kidney function novel biomarkers CKD progression determine improve eradication HCV .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>1 . Male female ≥ 18 year age 2 . HCV genotype 1 ≥ 1000 IU/mL 3 . 6 . Estimated glomerular filtration rate 1545mL/min/1.73m2 estimate CKDEpi equation 1 . Pregnant lactating female 2 . Uncontrolled depression psychiatric disease 3 . History presence form cancer within 3 year enrollment 4 . Experiencing lifethreatening cryoglobulinemic vasculitis require initiation rituximab , steroids plasmapheresis . 5 . Uncontrolled cardiovascular pulmonary disease 6 . Experiencing symptom attribute uremia 7 . Anticipated need begin renal replacement therapy next 6 month 8 . History kidney transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>CKD</keyword>
	<keyword>HCV</keyword>
</DOC>